RayKnowChina Research Map
Shortlist0

RecruitingOsteosarcomaPhase 2

Registered title, quoted from ClinicalTrials.gov

ARTEMIS-002: HS-20093 in Patients With Relapsed or Refractory Osteosarcoma and Other Sarcomas

An open trial on osteosarcoma, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 11 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 11

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteChinese PLA General Hospital中国人民解放军总医院BeijingHospital page
  2. Study siteFirst Affiliated Hospital of Sun Yat-sen University中山大学附属第一医院GuangzhouHospital page
  3. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  4. Study siteHunan Cancer Hospital湖南省肿瘤医院ChangshaHospital page
  5. Study sitePeking University People's Hospital北京大学人民医院BeijingHospital page
  6. Study siteSecond Affiliated Hospital, Zhejiang University浙江大学医学院附属第二医院HangzhouHospital page
  7. Study siteShanghai General Hospital上海市第一人民医院ShanghaiHospital page
  8. Study siteShanghai Sixth People's Hospital上海市第六人民医院ShanghaiHospital page
  9. Study siteSun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page
  10. Study siteTianjin Medical University Cancer Institute & Hospital天津医科大学肿瘤医院TianjinHospital page
  11. Study siteZhejiang Cancer Hospital浙江省肿瘤医院HangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT05830123, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Patients with histologically confirmed relapsed or refractory osteosarcoma or other sarcomas who have progressed upon first-line systemic treatment.

    Inclusion criterion 2

  3. Previous or current treatment with B7-H3 targeted therapy

    Exclusion criterion 2

    Prior treatment with a monoclonal antibody within 28 days prior to the first scheduled dose of HS-20093

    Exclusion criterion 4

    Radiotherapy with a limited field of radiation for palliation within 2 weeks, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093

    Exclusion criterion 5

    Any unresolved toxicities from prior therapy greater than Grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0 with the exception of alopecia or neurotoxicity.

    Exclusion criterion 11

    Patients who have received continuous steroid treatment for more than 30 days within 30 days before the first dose, or need long-term (≥ 30 days) steroid treatment, or who have other acquired and congenital immunodeficiency diseases, or have a history of organ transplantation

    Exclusion criterion 21

  4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1

    Inclusion criterion 5

  5. Diabetes ketoacidosis or hyperglycemia hypertonic occurring within 6 months before the first dose of the study drug, or the glycosylated hemoglobin value ≥ 7.5% in the screening period.

    Exclusion criterion 16

  6. At least one measurable lesion according to RECIST 1.1.

    Inclusion criterion 3

  7. The presence of active infectious diseases has been known before the first dose such as hepatitis B, hepatitis C, tuberculosis, syphilis, or human immunodeficiency virus HIV infection, etc.

    Exclusion criterion 22

  8. Females subjects must not be pregnant at screening or have evidence of non-childbearing potential

    Inclusion criterion 8

    Women who are breastfeeding or pregnant or planned to be pregnant during the study period.

    Exclusion criterion 26

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT05830123, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • At least age of 18 years at screening;
  • Patients with histologically confirmed relapsed or refractory osteosarcoma or other sarcomas who have progressed upon first-line systemic treatment.
  • At least one measurable lesion according to RECIST 1.1.
  • Agree to provide fresh or archival tumor tissue and peripheral blood samples.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1
  • Life expectancy >= 12 weeks
  • Men or women should be using adequate contraceptive measures throughout the study;
  • Females subjects must not be pregnant at screening or have evidence of non-childbearing potential
  • Signed and dated Informed Consent Form

Exclusion Criteria:

  • Treatment with any of the following:
  • Previous or current treatment with B7-H3 targeted therapy
  • Any cytotoxic chemotherapy, investigational agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093
  • Prior treatment with a monoclonal antibody within 28 days prior to the first scheduled dose of HS-20093
  • Radiotherapy with a limited field of radiation for palliation within 2 weeks, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093
  • Pleural or peritoneal effusion requiring clinical intervention. Pericardial effusion.
  • Major surgery within 4 weeks of the first dose of HS-20093.
  • Spinal cord compression or brain metastases.
  • Treatment with drugs that are predominantly CYP3A4 strong inhibitors or inducers or sensitive substrates of CYP3A4 with a narrow therapeutic range within 7 days of the first dose of study drug; or requiring treatment with these drugs during the study.
  • Currently receiving drugs known to prolong QT interval or may cause torsade de pointe; or requiring treatment with these drugs during the study.
  • Any unresolved toxicities from prior therapy greater than Grade 2 according to Common Terminology Criteria for Adverse Events (CTCAE) 5.0 with the exception of alopecia or neurotoxicity.
  • History of other primary malignancies.
  • Inadequate bone marrow reserve or organ dysfunction
  • Evidence of cardiovascular risk.
  • Severe, uncontrolled or active cardiovascular diseases.
  • Diabetes ketoacidosis or hyperglycemia hypertonic occurring within 6 months before the first dose of the study drug, or the glycosylated hemoglobin value ≥ 7.5% in the screening period.
  • Severe or poorly controlled hypertension.
  • Bleeding symptoms with apparent clinical significance or obvious bleeding tendency within 1 months prior to the first dose of HS-20093
  • Serious arteriovenous thrombosis events occurred within 3 months before the first dose.
  • Severe infections occurred within 4 weeks before the first dose.
  • Patients who have received continuous steroid treatment for more than 30 days within 30 days before the first dose, or need long-term (≥ 30 days) steroid treatment, or who have other acquired and congenital immunodeficiency diseases, or have a history of organ transplantation
  • The presence of active infectious diseases has been known before the first dose such as hepatitis B, hepatitis C, tuberculosis, syphilis, or human immunodeficiency virus HIV infection, etc.
  • Hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh Grade B or more severe cirrhosis.
  • Other moderate or severe lung diseases that may interfere with the detection or treatment of drug-related pulmonary toxicity or may seriously affect respiratory function.
  • Previous history of serious neurological or mental disorders, including epilepsy, dementia or severe depression and any other status that may interfere in assessment.
  • Women who are breastfeeding or pregnant or planned to be pregnant during the study period.
  • Vaccination or hypersensitivity of any level within 4 weeks prior to the first dose of HS-20093
  • History of severe hypersensitivity reaction, severe infusion reaction or allergy to recombinant human or mouse derived proteins.
  • Hypersensitivity to any ingredient of HS-20093.
  • Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator
  • Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments

Quoted from ClinicalTrials.gov, NCT05830123, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT05830123, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT05830123